

**ODONTOPREV S.A.**  
Corporate Taxpayer's ID (CNPJ/MF) 58.119.199/0001-51  
Corporate Registry (NIRE) No.: 35.300.156.668  
PUBLICLY HELD COMPANY

**MINUTES OF THE BOARD OF DIRECTOR'S MEETING  
HELD ON APRIL 28<sup>th</sup>, 2022**

**Day, Time and Place:** April 28<sup>th</sup>, 2022, at 03:00 pm, at the Company's headquarter located at Alameda Araguaia, 2104 - 21º Andar - Alphaville - CEP: 06455-000, na cidade de Barueri, Estado de São Paulo.

**Call notice:** The Call Notice was made according to the Company's Bylaws.

**Attendance:** All members of the Board of Directors, by videoconference, in accordance with Article 17 of the Company's Bylaws.

**Instatement:** Chairman: Manoel Antonio Peres; Secretary: André Chidichimo França.

**Agenda:** (i) the conclusion of the Share Buyback Program, approved on 10/28/2021; and (ii) To approve a Share Buyback Program, issued by the Company

**Decisions:** By unanimous vote of the members of the Board of Directors, decisions were the following:

- (i) Approval of the conclusion of the Share Buyback Program, approved on 10/28/2021, as a result of having reached the expected acquisition volume; and
- (ii) According to Article 18, XIV, of Company's Bylaws and the CVM Instruction n. 567/15 requirements and legal provisions met, it was approved a Share Buyback Program, issued by the Company, authorizing the acquisition up to 18,000,000 (eighteen million) ordinary shares, nominative and without par value, without capital reduction, representing 6.5% of the Company free float, and will occur through the use of resources held in the Earnings Reserve, and the Executive Directors shall determine the timing and quantity of shares to be effectively acquired, subject to the limits and validity of this authorization. The eventual decision to cancel the shares held in treasury will be disclosed to the market. In terms of Article 5 of CVM Instruction n. 567/15 and Attachment 30 – XXXVI of CVM Instruction 480/09 (Attachment I of the present Minute) the following is specified: (a) the objective of the Share Buyback Program is to maximize value creation, given that, in the Odontoprev's view, the current value of the shares does not reflect the fundamentals of the business model, return and opportunities ahead; (b) the Company may acquire up to 18,000,000 (eighteen million) ordinary shares, nominative and without par value, issued by the Company; (c) the maximum period for the authorized transaction settlement is up to 18 months, from April 29, 2022, being the Executive Officers to define the appropriate timing for the acquisitions; (d) the Company holds 274,874,172 (two hundred and seventy-four million, eight hundred and seventy seven thousand, one hundred and seventy-two) ordinary

shares nominative and without par value comprising the free float, according to definition to Article 8, Paragraph 3, of CVM Instruction n. 567/15, and 6,697,340 (six million, six hundred and ninety-seven thousand, three hundred and forty) shares nominative and without par value held as Treasury stock, registered until the present date; (e) the purchase price for the shares will be paid by means of allocation of available resources originating from Earnings Reserve, that, according to the Interim Financials of 03.31.2022, amounted to R\$275,020 thousand; and (f) Bradesco S.A. CTVM, located at Avenida Paulista, 1450 / 7th floor – São Paulo/SP will be the intermediary institution.

**Closure:** With no other deliberations, the meeting was suspended. The minutes were read, approved and signed by the present members. **Instatement:** Manoel Antônio Peres – President; Andre Chidichimo França – Secretary. Members of The Board of Directors: Manoel Antônio Peres, Ivan Luiz Gontijo Junior, Samuel Monteiro dos Santos Junior, César Suaki dos Santos, Murilo Cesar Lemos dos Santos Passos, Thaís Jorge de Oliveira e Silva and Américo Pinto Gomes

Barueri, April 28<sup>th</sup>, 2022.

**Instatement:**

---

**Manoel Antonio Peres**  
Chairman

---

**André Chidichimo França**  
Secretary

**ODONTOPREV S.A.**  
**Corporate Taxpayers Registration (CNPJ/MF) No.: 58.119.199/0001-51**  
**Corporate Registry (NIRE) No.: 35.300.156.668**  
**PUBLICLY HELD COMPANY**

**ATTACHMENT I OF THE BOARD OF DIRECTOR´S MEETING**  
**HELD ON APRIL 28TH, 2022**

Attachment 30-XXXVI of CVM Instruction 480/09

**1. Justify in detail the objective and the economic effects of the operation:**

The objective of the Share Buyback Program, approved at the Board of Director's Meeting on 04.28.2022, is to maximize value creation, given that, in the Odontoprev's view, the current value of the shares does not reflect the fundamentals of the business model, return and opportunities ahead.

**2. Inform the number of shares (i) comprising the free float and (ii) already held as treasury stock:**

(i) 274,874,172 ordinary shares comprising the free float and (ii) 6,697,340 shares held as Treasury stock, registered until the present date.

**3. Inform the number of shares that may be acquired or sold:**

The Company may acquire up to 18,000,000 ordinary shares, nominative and without par value, issued by the Company, representing 6.5% of the Company free float, traded at B3, under the code "ODPV3".

**4. Describe the principal characteristics of the derivative instruments which the company may use, if any:**

Not applicable. The Company does not use derivative instruments.

**5. Describe, if any, eventual agreements or existing voting guidance between the company and the counterparty to the operations:**

Not applicable, since the acquisition of shares issued by the Company will be conducted at B3, not having knowledge regarding the counterparty to the operations.

**6. In the event that operations are transacted outside organized securities markets, inform:**

**a. the maximum (minimum) price at which the shares will be acquired (sold):**

Not applicable, since the acquisition of shares issued by the Company will be conducted at B3, at market value.

**b. if the case, the reasons justifying the conducting of the transaction at prices of more than 10% (ten per cent) lower in the case of sale, at an average quotation, weighted by volume for the previous 10 (ten) trading days:**

Not applicable, since the acquisition of shares issued by the Company will be conducted at B3, at market value.

**7. Inform, if any, the impacts trading will have on the shareholding composition or the management structure of the corporation:**

Not applicable, given the acquisition of shares issued by the Company itself neither will there be an impact on the composition of shareholder composition nor the management structure of the Company.

**8. Identify the counterparties, if known and in the event that the counterparty is a party related to the company as set out in the accounting rules that cover this question, also supply information required by the Article 8 to CVM Instruction 481 of December 17, 2009:**

Not applicable, since the acquisition of shares issued by the Company will be conducted at B3, not having knowledge regarding the counterparty to the operations.

**9. Indicate the use of the funds generated, if the case:**

Not applicable, since the Company will not earn resources, and the acquired shares will be held in Treasury and also can be cancelled.

**10. Indicate the maximum term for settlement of the authorized operations:**

The buyback, object of the Buyback Program, may be made up to 18 months, and will run from April 29th, 2022 up to October 30th, 2023, inclusive, being the Board of Executive Officers to define the appropriate moment for the acquisitions.

**11. Identify institutions that will act as intermediaries, if any:**

The operations will be held by B3, and intermediated by Bradesco S.A. CTVM, with registered office at Avenida Paulista, 1.450 / 7th floor – São Paulo/SP, enrolled by Corporate Taxpayer's ID 61.855.045/0001-32.

**12. Specify the available funds to be used pursuant to Article 7, Paragraph 1 of CVM Instruction 567 of September 17, 2015:**

The share buyback will occur by means of allocation of available resources originating from Earnings Reserve, that, according to the Interim Financials as of 03.31.2022, amounted R\$275,020 thousand.

**13. Specify the reasons for which members of the Board of Directors feel comfortable that the buyback of shares will not have an adverse impact on the ability to comply with creditors or the payment of mandatory dividends, whether fixed or minimum:**

The Board of Directors understands that the settlement of the acquisition of shares issued by the Company is compatible with its financial situation, and that is comfortable regarding regulatory solvency requirements, foreseeing no impact on the ability to comply with obligations previously assumed. This conclusion is supported by the financial amount to be used for the Buyback Program, regarding: (i) the Company's amount of cash, cash equivalents and cash investments available and (ii) the expectation of cash generation and (iii) the absence of any bank financing or debt instrument with the capital market.